CClinicalTrials.gg
Status unknownNCT03053570Updated Feb 15, 2017

Study Comparing Pulmonary Vein Isolation With the Cryoballoon and Radiofrequency Energy(Contact Force) in the Treatment of Persistent Atrial Fibrillation (AF) (Cryo Vs CF in PerAF)

An interventional study of Cryoballoon and Radiofrequency Energy(Contact Force) in Persistent Atrial Fibrillation, sponsored by China Cardiometabolic Registries. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-02-15.

Sponsored by China Cardiometabolic Registries · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to perform a prospective, randomised study investigating the safety and efficacy of cryoballoon catheter ablation compared with radiofrequency ablation(contact force), in the treatment of persistent AF.

Read the detailed description

The hypotheses for this study is that cryothermal energy is as effective and safe as using radiofrequency energy in the treatment of persistent AF and is associated with a better long term outcome.

02

Conditions studied

  • Persistent Atrial Fibrillation

Browse trials for

Keywords

  • Cryoballoon
  • Contact Force
  • Persistent Atrial Fibrillation
03

In context

Atrial Fibrillation

3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.

This study's planned enrollment of 200 is above the median of 144 across 2,380 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

China Cardiometabolic Registries is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • persistent Atrial Fibrillation; Intolerant to antiarrhythmic medication; Both male or female; Age from 18 to 75 years old.

Exclusion criteria

Exclusion Criteria:

  • Acute myocardial infarction; Coronary artery stent history; Acute severe stroke; Abnormal liver and renal function.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Cryoballoon

    Device: Cryoballoon · Device: Radiofrequency Energy(Contact Force)

  • Experimental
    Radiofrequency Energy(Contact Force)

    Device: Cryoballoon · Device: Radiofrequency Energy(Contact Force)

Interventions

  • DeviceCryoballoon

    use Cryoballoon to isolation the Pulmonary Vein

  • DeviceRadiofrequency Energy(Contact Force)

    use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein

06

What researchers measure

Primary outcomes

  1. Number of participants with successful Pulmonary Vein Isolation

    Time frame: in one year

07

Study locations

1 of 1 sites recruiting
  • First Affiliated Hospital of Xinjiang Medical University
    Urumqi, Xinjiang 830011, China
    • Baopeng Tang · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03053570
Lead sponsor
China Cardiometabolic Registries
Responsible party
Sponsor
First posted
Feb 15, 2017
Start date
Mar 1, 2017 (estimated)
Primary completion
Dec 31, 2018 (estimated)
Completion
Dec 31, 2018 (estimated)
Last update
Feb 15, 2017

Study contacts

Baopeng Tang, PhD
Contact
tangbaopeng1111@163.com
+86 13579881111
Baopeng Tang
study chair · First Affiliated Hospital of Xinjiang Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion